J Clin Neurol.  2009 Jun;5(2):53-64. 10.3988/jcn.2009.5.2.53.

Muscle-Specific Receptor Tyrosine Kinase Antibody Positive Myasthenia Gravis Current Status

• Oh SJ

• KMID: 2287655
• DOI: http://doi.org/10.3988/jcn.2009.5.2.53

Abstract

Muscle-specific tyrosine-kinase-antibody-positive myasthenia gravis (MuSK-MG) has emerged as a distinct entity since 2001. This disease has been reported worldwide, but with varying rates among patients with generalized acetylcholine-receptor-antibody-negative MG. MuSK-MG was detected in approximately 37% of generalized acetylcholine receptor antibody-negative MG. MuSK-MG patients were predominantly female with more prominent facial and bulbar involvement and more frequent crises. Disease onset tended to be earlier. Patients tended to have a relatively poor edrophonium response but showed prominent decrement in the repetitive nerve stimulation test in the facial muscles. Patients were more likely to display poor tolerance of, or a lack of improvement with, anticholinesterase agents. Somewhat better response was observed with steroids and plasma exchange. Most were managed successfully with aggressive immunomodulatory therapies, although a higher proportion of MuSK-MG patients had a refractory course when compared with other forms of generalized MG. I present here an up-to-date overview on MuSK-MG based on our experience at the University of Alabama at Birmingham and the existing literature.

Keyword

myasthenia gravis; muscle-specific tyrosine-kinase-antibody; seronegative myasthenia gravis

MeSH Terms

Acetylcholine
Alabama
Cholinesterase Inhibitors
Edrophonium
Facial Muscles
Female
Humans
Immunomodulation
Myasthenia Gravis
Plasma Exchange
Protein-Tyrosine Kinases
Steroids
Tyrosine
Acetylcholine
Cholinesterase Inhibitors
Edrophonium
Protein-Tyrosine Kinases
Steroids
Tyrosine

Figure

• 

  Fig. 1 Simplitied illustration of neuromuscular junction in normal and MuSK-MG. MuSK-MG: muscle-specific tyrosine kinase antibody positive-MG.

• 

  Fig. 2 Classical repetitive nerve stimulation response in MuSK-MG. A remarkable decremental (31%) response in the orbicularis oculi (Orb oculi) muscle and normal response (3%) in the abductor digiti quinti (ADQ) muscle. Low CMAP amplitude is also noted in Orb oculi muscle. MuSK-MG: muscle-specific tyrosine kinase antibody positive-MG, CMAP: compound muscle action potential.

Reference

1. Simpson JA. Myasthenia gravis: a new hypothesis. Scott Med J. 1960. 5:419–436.

2. Lindstrom JM, Seybold ME, Lennon VA, Whittingham S, Duane DD. Antibody to acetylcholine receptor in myasthenia gravis. Prevalence, clinical correlates, and diagnostic value. Neurology. 1976. 26:1054–1059.

3. Hoch W, McConville J, Helms S, Newsom-Davis J, Melms A, Vincent A. Auto-antibodies to the receptor tyrosine kinsase MuSK in patients with myasthenia gravis, without acetylcholine receptor antibodies. Nat Med. 2001. 7:365–368.

4. Soliven BC, Lange DJ, Penn AS, Younger D, Jeretzki A 3rd, Lovelace RE, et al. Seronegative maysthenia gravis. Neurology. 1988. 38:514–517.

5. Oh SJ. Electrophysiological characteristics in seronegative myasthenia gravis. Ann N Y Acad Sci. 1993. 681:584–587.

6. Sanders DB, Howard JF, Massey JM, Mihovilovic M, Ollanow CW. Seronegative myasthenia gravis. Ann Neurol. 1987. 22:126.

7. Mossman S, Vincent A, Newsom-Davis J. Myasthenia gravis without acetylcholine-receptor antibody: a distinct disease entity. Lancet. 1986. 1:116–119.

8. Selcen D, Fukuda T, Shen XM, Engel AG. Are MuSK antibodies the primary cause of myasthenic symptoms? Neurology. 2004. 62:1945–1950.

9. Shiraishi H, Motomura M, Yoshimura T, Fukudome T, Fukuda T, Nakao Y, et al. Acetylcholine receptors loss and postsynptic damage in MuSK antibody-positive myasthenia gravis. Ann Neurol. 2005. 57:289–293.

10. Jha S, Xu K, Maruta T, Oshima M, Mosier DR, Atassi MZ, et al. Myasthenia gravis induced in mice by immunization with the recombinanat extracellular domain of rat muscle-specific kinase (MuSK). J Neuroimmunol. 2006. 175:107–117.

11. Shigemoto K, Kubo S, Maryyama N, Hato N, Yamada H, Jie C, et al. Induction of myasthenia by immunization against muscle-specific kinase. J Clin Invest. 2006. 116:1016–1024.

12. Cole RN, Reddel SW, Gervásio OL, Phillips WD. Anti-MuSK patient antibodies disrupt the mouse neuromuscular junction. Ann Neurol. 2008. 63:782–789.

13. Saka E, Topcuoglu MA, Akkaya B, Galati A, Onal MZ, Vincent A. Thymus changes in anti-MuSK-positive and- negative myasthenia gravis. Neurology. 2005. 65:782–783.

14. Lavrnic D, Losen M, Vujic A, De Baets M, Hajdukovic LJ, Stojanovic V, et al. The features of myasthenia gravis with autoantibodies to MuSK. J Neurol Neurosurg Psychiatry. 2005. 76:1099–1102.

15. Evoli A, Bianchi MR, Riso R, Minicuci GM, Batocchi AP, Servidei S, et al. Response to therapy in myasthenia gravis with anti-MuSK antibodies. Ann N Y Acad Sci. 2008. 1132:76–83.

16. Lauriola L, Ranelletti F, Maggiano N, Guerriero M, Punzi C, Marsili F, et al. Thymius changes in anti-MuSK-positive and -negative myasthenia gravis. Neurology. 2005. 64:536–538.

17. Leite MI, Strobel P, Jones M, Micklem K, Moritz R, Gold R, et al. Fewer thymic changes in MuSK antibody-positive than in MuSK antibody-negative MG. Ann Neurol. 2005. 57:444–448.

18. Sanders DB, El-Salem K, Massey JM, McConville J, Vincent A. Clinical aspects of MuSK antibody positive seronegative MG. Neurology. 2003. 60:1978–1980.

19. Padua V, Tenali P, Aprile I, Caliandro P, Bartoccioni E, Evoli A. Seronegative myasthenia gravis: comparison of neurophysiological picture in MuSK+ and MuSK- patients. Eur J Neurol. 2006. 13:273–276.

20. Martignago S, Fanin M, Albertini E, Pegoraro E, Angelini C. Muscle histopathology in myasthenia gravis with antibodies against MuSK and AChR. Neuropathol and Appl Neurobiol. 2009. 35:103–110.

21. Farrugia ME, Robson MD, Clover L, Anslow P, Newsom-Davis J, Kennett R, et al. MRI and clinical studies of facial and bulbar involvement in MuSK antobody-associated myasthenia gravis. Brain. 2006. 129:1481–1492.

22. Shirashi H, Motomura M, Yoshimura T, Fukudome T, Fukuda T, Nakao Y, et al. Acetylcholine receptors loss and postsynaptic damage in MuSK antibody positrive myasthenia gravis. Ann Neurol. 2005. 57:289–293.

23. McConville J, Farrugia ME, Beeson D, Kishore U, Metcalfe R, Newsom-Davis J, et al. Detection and characterization of MuSK antibodies in seronegative myasthenia gravis. Ann Neurol. 2004. 55:580–584.

24. Caress JB, Hunt CH, Batish SD. Anti-MuSK myasthenia gravis presenting with purely ocular findings. Arch Neurol. 2005. 62:1002–1003.

25. Hanisch E, Eger K, Zierz S. MuSk-antibody positive pure ocular myasthenia gravis. J Neurol. 2006. 253:659–660.

26. Chan JW, Orrison WW. Ocular myathenia: a rare presentation with MuSK antibody and bilateral extraocular muscle atrophy. Br J Ophthalmol. 2007. 91:842–843.

27. Kupersmith MJ, Latkany R, Homel P. Developmen of generalized disease at 2 years in patients with ocular myasthenia gravis. Arch Neurol. 2003. 60:243–248.

28. Zhou L, McConville J, Chaudhry V, Adams RN, Skolasky RL, Vincent A, et al. Clinical comparison of muscle-specific tyrosine kinase (MuSK) antibody-positive and -negative myasthenic patients. Muscle Nerve. 2004. 30:55–60.

29. Evoli A, Tonali PA, Padua L, Monaco ML, Scuderi F, Batocchi AP, et al. Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis. Brain. 2003. 126:2304–2311.

30. Lee JY, Sung JJ, Cho JY, Oh DH, Kim HJ, Park JH, et al. MusK antibody-positive seronegative myasthenia gravis in Korea. J Clin Neurosci. 2006. 13:353–355.

31. NiKs EH, Kuks JB, Verschuuren JJ. Epidemiology of myathenia gravis with anti-muscle specific kinase antibodies in The Netherlands. J Neurol Neurosurg Psychiatry. 2007. 78:417–418.

32. Nemoto Y, Kuwabara S, Misawa S, Kawaguchi N, Hattori T, Takamori M, et al. Patterns and severity of neuromuscular transmission failure in seronegative myasthenia gravis. J Neurol Neurosurg Psychiatry. 2005. 76:714–718.

33. Ohta K, Shigemoto K, Fujinami A, Maruyama N, Konishi T, Ohta M. Clinical and experimental features of MuSK antibody positive MG in Japan. Eur J Neurol. 2007. 14:1029–1034.

34. Kostera-Pruszczyk A, Kamińska A, Dutkiewicz M, Emeryk-Szajewska B, Strugalska-Cynowska MH, Vincent A, et al. MuSK-positive myasthenia gravis is rare in the Polish population. Eur J Neurol. 2008. 15:720–724.

35. Ohta K, Shigemoto K, Kubo S, Maruyama N, Abe Y, Ueda N, et al. MuSk antibodies in AChR Ab-seropositive MG vs AChR Ab-seronegative MG. Neurology. 2004. 62:2132–2133.

36. Ohta K, Shigemoto K, Kubo S, Maruyama N, Abe Y, Ueda N, et al. MuSK Ab described in seropositive MG sera found to be Ab to alkaline phosphatase. Neurology. 2004. 65:1988.

37. Rostedt Punga A, Ahlqvist K, Bartoccioni E, Scuderi F, Marino M, Suomalainen A, et al. Neurophysiological and mitochondrial abnormalities in MuSK antibody seropositive myasthenia gravis compared to other immunological subtypes. Clin Neurophysiol. 2006. 117:1434–1443.

38. Romi F, Aarli JA, Gilhus NE. Seronegative myasthenia gravis: disease severity and prognosis. Eur J Neurol. 2005. 12:413–418.

39. Deymeer F, Gungor-Tuncer O, Yilmaz V, Parman Y, Serdaroglu P, Ozdemir C, et al. Clinical comparison of anti-MuSK- vs antiAChR-positive and seronegative myasthenia gravis. Neurology. 2007. 68:609–611.

40. Wolfe GI, Oh SJ. Clinical phenotype of muscle-specific tyrosine kinase-antibody-positive myasthenia gravis. Ann N Y Acad Sci. 2008. 1132:71–75.

41. Oh SJ, Morgan MB, Lu L, Hatanaka Y, Hemmi S, Young A, et al. Racial differences in myasthenia gravis in Alabama. Muscle Nerve. 2009. 39:328–332.

42. Burns T, Wolfe GI, Nations S, Trivedi J, Phillips LT, Phillips L, et al. Variable MuSK antibody positive rates among seronegative MG in the United States (Abstract). Neurology. 2008. 70:suppl 1. A302.

43. Stickler DE, Massey JM, Sanders DB. MuSK-antibody positive myasthenia gravis: clinical and electrodiagnostic patterns. Clin Neurophysiol. 2005. 116:2065–2068.

44. Bartoccioni E, Scuderi F, Minicuci GM, Mario M, Ciarffa F, Evoli A. Anti-MuSK antibodies: correlation with myasthenia gravis severity. Neurology. 2006. 67:505–507.

45. Pasnoor M, Wolfe G, Nations S, Trivedi J, Barohn RJ, Hervbelin L, et al. Clinical findings in MuSK-antibody positive myasthenia gravis. A U.S. Experience. Muscle Nerve. 2009. (In Press).

46. Spengos K, Vassilopoulou S, Papadimas G, Tsivqoulis G, Karandreas N, Zambelis T, et al. Dropped head syndrome as prominent clinical feature in MuSK-positive myathenia gravis with thymus hyperplasia. Neuromuscul Disord. 2008. 18:175–177.

47. Béhin A, Mayer M, Kassis-Makhoul B, Jugie M, Espil-Taris C, Ferrer X, et al. Severe neonatal myasthenia due to materanal anti-MuSK antibodeies. Neuromuscul Disord. 2008. 18:443–446.

48. Niks EH, Verrips A, Semmekrot BA, Prick MJ, Vincent A, van Tol MJ, et al. A transient neonatal myasthenic syndrome with anti-musk antibodies. Neurology. 2008. 70:1215–1216.

49. Sylva M, van der Kooi AJ, Grolman W. Dyspnoea due to vocal fold abduiction paresis in anti-MuSK myasthenia gravis. J Neurol Neurosurg Psychiatry. 2008. 79:1083–1084.

50. Hara K, Mashima T, Matsuda A, Tanaka K, Tomita M, Shiraishi H, et al. Vocal cord paralysis in myasthenia gravis with anti-MuSK antibodies. Neurology. 2007. 68:621–622.

51. Díaz-Manera J, Rojas-García R, Gallardo E, Juárez C, Martínez-Domeño A, Martínez-ramírez S, et al. Antibodies to AChR, Musk and VGKC in a patient with myasthenia gravis and Morvan's syndrome. Nat Clin Pract Neurol. 2007. 3:405–410.

52. Hatanaka Y, Hemmi A, Morgan MB, Scheufele ML, Claussen GC, Wolfe GI, et al. Nonresponsiveness to anticholinesterase agents in patients with MuSK-antibody-positive MG. Neurology. 2005. 65:1508–1509.

53. Wolfe GI, Trivedi JR, Oh SJ. Clinical review of Muscle-Specific Tyrosine Kinase-Antibody positive myasthenia gravis. Jr Clin Neuromuscular Dis. 2007. 8:217–224.

54. Punga AR, Flink R, Askmark H, Stålberg EV. Cholinergic neuromuscular hyperactivity in patients with myasthenia gravis seropositive for MuSK antibody. Muscle Nerve. 2006. 34:111–115.

55. Oh SJ, Hatanaká Y, Hemmi S, Young AM, Scheufele ML, Nations SP, et al. Repetitive nerve stimulation of facial muscles in MuSK antibody positive myasthenia gravis. Muscle Nerve. 2006. 33:500–504.

56. Kuwarbara S, Nemoto Y, Misawa S, Takahashi H, Kawaguchi N, Hattori T. Anti-MuSK positive myasthenia gravis: neuromuscular transmission failure in facial and limb muscles. Acta Neurol Scand. 2007. 115:126–128.

57. Farrugia ME, Kennett RP, Newsom-Davis J, Hilton-Jones D, Vincent A. Single-fiber electromyography in limb and facial muscles in muscle-specific kinase antibody and acetylcholine receptor antibody myasthenia gravis. Muscle Nerve. 2006. 33:568–570.

58. Farrugia ME, Kennett RP, Hilton-Jones D, Newsom-Davis J, Vincent A. Quantitative EMG of facial muscles in myasthenia patients with MuSK antibodies. Clin Neurophysiol. 2007. 118:269–277.

59. Odabasi Z, Kuruoglu R, Oh SJ. Turns-ampliutude analysis and motor unit potential analysis in myasthenia gravis. Acta Neurol Scand. 2000. 101:315–320.

60. Sanders D, Massey J, Juel V. Muscle antibody positive myasthenia gravis: response to treatment in 31 patients. Neurology (asbtract). 2007. 68:A299.

61. Drachman DB, Jones RJ, Brodsky RA. Treatment of refractory myasthenia: "rebooting" with high-dose cyclophosphamide. Ann Neurol. 2003. 5:29–34.

62. Hain B, Jordan K, Deschauer M, Zierz S. Successful treatment of MuSK antibody-positive myasthenia gravis with rituximab. Muscle Nerve. 2006. 33:575–580.

63. Hain B, Jordan K, Deschauer M, Zierz S. Successful treatment of MuSK antibody-positive myasthenia gravis with rituximab. Muscle Nerve. 2006. 33:575–580.

64. Takahashi H, Kawaguchi N, Nemoto Y, Hattori T. High-dose intravenous immunoglobulin for the treatment of MuSK antibody-positive seronegative myasthenia gravis. J Neurol Sci. 2006. 247:239–241.

65. Diaz-Manera J, Rajas-Garcia R, Juarez C, Pradas J, Gallardo E, Illa I. Are immunosuppressors as effective in MuSK+ MG as in AChR+ MG patients? Evaluation of 150 myashenic patients treated with the same protocol (abstract). Neurology. 2007. 68:A300.